Chronic heart failure in adults
KEYWORDS: heart, failure, heart failure, chronic, chronic heart, adults, quality, data, statement, adults chronic, nice, specialist, care, cardiac, fraction

to 1.4.4, 1.4.8 to 1.4.12, 1.7.1 and 1.7.2 and NICE's technology appraisal guidance on ivabradine, sacubitril valsartan, dapagliflozin, and empagliflozin for treating chronic heart failure with reduced ejection fraction] Equality and diversity considerations ACE inhibitors are less effective in people of African or Caribbean family origin. Healthcare professionals should take this into account and ensure that the person receives additional treatment promptly if needed. Quality statement 4: Review after changes in medication Quality statement Adults with chronic heart failure have a review within 2 weeks of any change in the dose or type of their heart failure medication. [2016] Rationale Medication to treat chronic heart failure can cause side effects, including dehydration, low blood pressure, a low heart rate and renal impairment. Some may initially and temporarily make heart failure symptoms worse. When the dose or type of medication for chronic heart failure is changed, the person should have a review within 2 weeks to monitor the effects. This can also include a review of the effectiveness of the medication and whether any further changes or referral to other members of the multidisciplinary team are needed. Quality measures The following measures can be used to assess the quality of care
